HER-2/neu Testing in Breast Carcinoma: A Combined Immunohistochemical and Fluorescence In Situ Hybridization Approach

This publication has 17 references indexed in Scilit:

• The HercepTest Assay: Another Perspective
  Journal of Clinical Oncology, 1999
• Increased HER2 With U.S. Food and Drug Administration-Approved Antibody
  Journal of Clinical Oncology, 1999
• erbB-2, p53, and Efficacy of Adjuvant Therapy in Lymph Node-Positive Breast Cancer
  JNCI Journal of the National Cancer Institute, 1998
• Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment.
  Journal of Clinical Oncology, 1998
• Critical determination of the frequency of c-erbB-2 amplification in breast cancer
  British Journal of Cancer, 1994
• c-erbB-2 Expression and Response to Adjuvant Therapy in Women with Node-Positive Early Breast Cancer
  New England Journal of Medicine, 1994
• Analysis of cerbB2 expression using a panel of 6 commercially available antibodies
  Pathology, 1994
• HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma.
  Journal of Clinical Oncology, 1992
• Assessment of Antigen Damage in Immunohistochemistry: The Vimentin Internal Control
  American Journal of Clinical Pathology, 1991
• c‐erbB‐2 and c‐erbA‐1 (ear‐1) Gene Amplification and c‐erbB‐2 Protein Expression in Japanese Breast Cancers: Their Relationship to the Histology and Other Disease Parameters
  Japanese Journal of Cancer Research, 1990